MAPT and Alzheimer disease: The results showed that rsEEG alpha source activities in the parietal, temporal, and occipital regions were significantly reduced in the ADMCI group compared to both the Healthy control group and the matched MCI group not due to AD (noADMCI), the neurobiological AD diagnosis being determined by the standard diagnostic CSF Aβ42 and p-tau biomarkers of the NIA-AA Framework in the use of biomarkers in AD [1,2].